GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 EV-to-FCF is 13.97 as of Jul. 01, 2026, which is 29% below its 10-year median of 19.65. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 560 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 65.54% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GlaxoSmithKline Pakistan's Enterprise Value is ₨108,358 Mil.
GlaxoSmithKline Pakistan's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₨7,756 Mil. Therefore, GlaxoSmithKline Pakistan's EV-to-FCF for today is 13.97.
The historical rank and industry rank for GlaxoSmithKline Pakistan's EV-to-FCF or its related term are showing as below:
KAR:GLAXO'
s EV-to-FCF Range Over the Past 10 Years
Min: -131.22 Med: 19.65 Max: 132.31
Current: 13.83
During the past 13 years, the highest EV-to-FCF of GlaxoSmithKline Pakistan was 132.31. The lowest was -131.22. And the median was 19.65.
KAR:GLAXO's EV-to-FCF is ranked better than 65.54% of 560
companies
in the Drug Manufacturers industry
Industry Median: 20.52
vs KAR:GLAXO: 13.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GlaxoSmithKline Pakistan's PE Ratio (TTM) for today is calculated as:
GlaxoSmithKline Pakistan's share price for today is ₨370.25.
GlaxoSmithKline Pakistan's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨33.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
GlaxoSmithKline Pakistan EV-to-FCF Related Terms
GlaxoSmithKline Pakistan EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's EV-to-FCF falls into.
GlaxoSmithKline Pakistan's current Enterprise Value is ₨108,358 Mil.
GlaxoSmithKline Pakistan's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨7,756 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a EV-to-FCF of 13.97 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 29% below median its historical median of 19.65. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #193 out of 560 companies in the Drug Manufacturers industry, placing it in the top 34.5%.
Is GlaxoSmithKline Pakistan's EV-to-FCF too high?
GlaxoSmithKline Pakistan's current EV-to-FCF of 13.97 is 29% below median its 10-year median of 19.65. The Drug Manufacturers industry median EV-to-FCF is 20.52. GlaxoSmithKline Pakistan's value of 13.97 is 31.9% below this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #193 out of 560 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #193 out of 560 companies for EV-to-FCF. This puts GlaxoSmithKline Pakistan in the upper half of its industry. The industry median EV-to-FCF is 20.52. GlaxoSmithKline Pakistan's value of 13.97 is 31.9% below this benchmark. While the company's 10-year median is 19.65 vs. the industry median of 20.52, GlaxoSmithKline Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.52, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current EV-to-FCF of 13.97 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current EV-to-FCF is 13.97, which is 29% below median its own 10-year median of 19.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current EV-to-FCF is 13.97, which is 29% below median its 10-year median of 19.65 and 31.9% below the Drug Manufacturers industry median of 20.52. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current EV-to-FCF is 13.97 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
EV-to-FCF: 13.97 (29% below median its 10-year median of 19.65)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 31.9% below the Drug Manufacturers median (#193 of 560)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
